HealthInvest Partners’s Cabaletta Bio CABA Stock Holding History

HealthInvest Partners’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-182,354	Closed	-$253K	–	38
2025 Q1	$253K	Sell	182,354 -65,100	-26%	-$139K	0.11%	37
2024 Q4	$554K	Buy	247,454 +78,932	+47%	+$277K	0.26%	36
2024 Q3	$795K	Buy	168,522 +104,201	+162%	+$603K	0.37%	35
2024 Q2	$481K	Sell	64,321 -13,219	-17%	-$162K	0.29%	37
2024 Q1	$1.32M	Buy	77,540 +56,540	+269%	+$1.21M	0.8%	30
2023 Q4	$477K	Buy	+21,000	New	+$353K	0.37%	42

Other funds holding CABA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

HealthInvest Partners's CABA Position: Q2 2025 in Review

HealthInvest Partners sold out of Cabaletta Bio (CABA) in Q2 2025, closing a stake of 182,354 shares — an estimated $253K sold.

HealthInvest Partners first reported a position in CABA in Q4 2023 and held it in 6 quarters. The position peaked at $1.32M in Q1 2024. 86 funds tracked by Wall St. Rank hold CABA as of Q2 2025.

HealthInvest Partners reported no remaining Cabaletta Bio position as of Q2 2025 after selling out during the quarter.
HealthInvest Partners sold 182,354 Cabaletta Bio shares in Q2 2025, an estimated $253K.
HealthInvest Partners first reported a position in Cabaletta Bio in Q4 2023 and held it in 6 quarters.
HealthInvest Partners's Cabaletta Bio position peaked at $1.32M in Q1 2024.
86 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2025.

Based on HealthInvest Partners's 13F filing for Q2 2025, filed 14 Jul 2025.